Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Expert Sheds Light on Rapid Progress in Relapsed/Refractory Myeloma

October 8th 2019

Ivan M. Borrello, MD, discusses the most impactful agents that have entered the relapsed/refractory setting of multiple myeloma and details some of the guiding principles of treatment selection.

Dr. Stadtmauer on Utility of Selinexor in Multiple Myeloma

October 4th 2019

Edward A. Stadtmauer, MD, discusses the use of selinexor in patients with heavily pretreated, relapsed/refractory multiple myeloma.

FDA Approves Frontline Daratumumab Regimen for Transplant-Eligible Myeloma

September 26th 2019

The FDA has approved daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Selinexor Improves Late-Stage Treatment Options for Multiple Myeloma

September 25th 2019

Sundar Jagannath, MBBS, discusses the significance the selinexor (Xpovio) approval has for patients with myeloma, the tolerability of the agent, and the management of related adverse events.

Dr. Borrello on Selinexor in Penta-Refractory Multiple Myeloma

September 21st 2019

Ivan M. Borrello, MD, associate professor of oncology, Johns Hopkins Medicine, discusses the use of selinexor (Xpovio) in the treatment of patients with penta-refractory multiple myeloma.

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma

September 20th 2019

Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.

Dr. Chari on Using Selinexor in Multiple Myeloma Treatment

September 20th 2019

Ajai Chari, MD, discusses the use of selinexor in multiple myeloma treatment.

Mounting Advances Make Waves Across Myeloma Spectrum

September 20th 2019

Sarah M. Larson, MD, discusses trials with the potential to shift treatment strategies in the frontline and relapsed/refractory settings of multiple myeloma and remaining research questions in the field.

Risk Patterns Prior to Progression From MGUS to Myeloma Call for Annual Assessments

September 20th 2019

Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance, the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years.

Dr. Parekh on Using Genomics in Multiple Myeloma Treatment

September 20th 2019

Samir Parekh, MBBS, discusses using genomics to treat patients with multiple myeloma.

Dr. Santomasso on Managing CNS Toxicity from CAR T-Cell Therapy for B-Cell Lymphoma

September 17th 2019

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Daratumumab Plus Carfilzomib and Dexamethasone Improves PFS in Myeloma

September 17th 2019

Adding daratumumab to carfilzomib and dexamethasone improved progression-free survival in patients with relapsed/refractory multiple myeloma, according to topline findings from the phase III CANDOR study.

Selinexor Triplet Highly Active in Relapsed Myeloma

September 16th 2019

The all-oral triplet regimen of 60 mg of weekly selinexor plus lenalidomide and dexamethasone appears to be highly active and well-tolerated in patients with relapsed, refractory multiple myeloma, particularly in patients who did not receive prior lenalidomide, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop.

Dr. Richardson on Results of the HORIZON Trial in Relapsed/Refractory Multiple Myeloma

September 16th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses interim results of the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Dr. Mateos on Frail Patients With Multiple Myeloma in the ARROW Trial

September 16th 2019

Maria-Victoria Mateos, MD, PhD, associate professor of medicine, and director of the Myeloma unit at the University Hospital of Salamanca in Spain, discusses the impact of performance status on the outcomes of patients with multiple myeloma in the phase III ARROW trial.

Anti-BCMA BiTE AMG 701 Shows Preclinical Promise in Multiple Myeloma

September 16th 2019

AMG 701, a half-life–extended anti-BCMA bispecific T-cell engager, showed promising in vitro antimyeloma activity and characteristics suitable for once-weekly dosing in patients with multiple myeloma, according to findings presented at the 17th International Myeloma Workshop.

Kumar Discusses Path Forward for Venetoclax in Myeloma

September 16th 2019

Shaji Kumar, MD, discusses the addition of the BCL-2 inhibitor venetoclax to the combination of bortezomib and dexamethasone significantly improved progression-free survival, overall response rate, very good partial response, and minimal residual disease negativity rates in the phase III BELLINI trial in relapsed/refractory patients with multiple myeloma.

Melflufen Regimen Elicits Activity in Relapsed Myeloma With Extramedullary Disease

September 16th 2019

Melflufen and dexamethasone demonstrated encouraging activity in patients with relapsed/refractory multiple myeloma with and without extramedullary disease, with response rates higher than those observed in prior studies of other agents.

Dr. Usmani on Impact of BCMA on the Myeloma Treatment Landscape

September 15th 2019

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.

Daratumumab Plus VRd Shows Improved sCR in Transplant-Eligible, Newly Diagnosed Myeloma

September 15th 2019

The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone for transplant-eligible patients with newly diagnosed multiple myeloma improved the depth of response without affecting stem cell mobilization or hematopoietic reconstitution.